Back to top
more

BioSpecifics Technologies Corp (BSTC)

(Delayed Data from NSDQ)

$66.72 USD

66.72
62,398

+0.21 (0.32%)

Updated May 3, 2019 04:00 PM ET

After-Market: $66.90 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

0 items in cart

[BSTC]

Reports for Purchase

Showing records 1 - 20 ( 56 total )

Industry: Medical - Drugs

Record: 1

10/20/2020

Company Report

Pages: 5

Endo Acquires BioSpecifics; Downgrade to Neutral with $88.50 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 2

08/11/2020

Company Report

Pages: 6

Better-Than-Projected 2Q20 Numbers; New XIAFLEX Indications; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 3

07/07/2020

Company Report

Pages: 6

FDA Approves CCH for Cellulite Treatment; Reiterate Buy; Raising PT to $100

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 4

06/16/2020

Company Report

Pages: 6

Medical Device Cellulite Treatment Not a Direct Threat, in Our View; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 5

05/12/2020

Company Report

Pages: 6

1Q20 Financials; Cellulite Approval Decision Nears; New CEO Appointed; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 6

03/17/2020

Company Report

Pages: 6

4Q and Full-Year 2019 Financial Results Reported; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 7

11/20/2019

Company Report

Pages: 5

FDA Accepts Regulatory Filing in Cellulite Treatment; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 8

11/11/2019

Company Report

Pages: 4

3Q19 Financial Results Reported; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 9

10/11/2019

Company Report

Pages: 7

New Chief Executive Officer Appointed; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 10

09/09/2019

Company Report

Pages: 6

Critical Cellulite CCH Biologics License Application Submitted; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 11

08/12/2019

Company Report

Pages: 6

Revenue In-Line, Healthy Bottom-Line Beat; Reiterate Buy; Raising PT to $90

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 12

05/13/2019

Company Report

Pages: 5

1Q19 Financial Results Reported; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 13

04/03/2019

Company Report

Pages: 6

2018 Financial Results Reported; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 14

03/19/2019

Company Report

Pages: 6

Leadership Transition Under Way; Business Continues; Reiterate Buy; Raising Price Target to $85

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 15

01/25/2019

Company Report

Pages: 7

New Executive Officer Appointed; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 16

11/12/2018

Company Report

Pages: 6

3Q18 Financial Results Reported; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 17

11/08/2018

Company Report

Pages: 7

CCH Met Primary Endpoint in Two Phase 3 Trials in Cellulite; Reiterate Buy and Raise Price Target to $81

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 18

11/01/2018

Company Report

Pages: 6

Positive Phase 1 Data in Uterine Fibroids; Reiterate Buy and Raise Price Target to $72

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 19

08/10/2018

Company Report

Pages: 6

2Q18 Results Reported; Xiaflex Sales up 27%; Cellulite Pivotal Data in 4Q18; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 20

07/05/2018

Company Report

Pages: 5

No Disruption in Operations; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party
// eof